ATE352289T1 - Mittel zur oralen verabreichung - Google Patents

Mittel zur oralen verabreichung

Info

Publication number
ATE352289T1
ATE352289T1 AT96912281T AT96912281T ATE352289T1 AT E352289 T1 ATE352289 T1 AT E352289T1 AT 96912281 T AT96912281 T AT 96912281T AT 96912281 T AT96912281 T AT 96912281T AT E352289 T1 ATE352289 T1 AT E352289T1
Authority
AT
Austria
Prior art keywords
oral administration
agents
composition
tasting drug
äobjectü
Prior art date
Application number
AT96912281T
Other languages
English (en)
Inventor
Toshio Yajima
Kuniaki Ishii
Shigeru Itai
Masami Nemoto
Kouji Suetake
Nobuyoshi Tsukui
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE352289T1 publication Critical patent/ATE352289T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96912281T 1995-05-02 1996-04-30 Mittel zur oralen verabreichung ATE352289T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10833895 1995-05-02

Publications (1)

Publication Number Publication Date
ATE352289T1 true ATE352289T1 (de) 2007-02-15

Family

ID=14482165

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96912281T ATE352289T1 (de) 1995-05-02 1996-04-30 Mittel zur oralen verabreichung

Country Status (12)

Country Link
US (1) US5972373A (de)
EP (1) EP0826376B1 (de)
JP (1) JP3470198B2 (de)
KR (1) KR100404293B1 (de)
CN (1) CN1170596C (de)
AT (1) ATE352289T1 (de)
AU (1) AU694655B2 (de)
CA (1) CA2219991C (de)
DE (1) DE69636864T2 (de)
DK (1) DK0826376T3 (de)
ES (1) ES2279519T3 (de)
WO (1) WO1996034628A1 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
KR100514330B1 (ko) * 1997-12-31 2006-02-17 주식회사 중외제약 난용성 약물을 함유하는 코팅정
PE20000601A1 (es) * 1998-03-23 2000-07-25 Gen Mills Inc Encapsulado de componentes en productos comestibles
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
HK1040191A1 (zh) * 1998-07-31 2002-05-31 大塚制药株式会社 具有改良味道的药物组合物
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
CA2367373C (en) * 1999-03-17 2011-09-20 Daiichi Pharmaceutical Co., Ltd. Medicinal compositions
PL198797B1 (pl) * 1999-03-31 2008-07-31 Janssen Pharmaceutica Nv Zastosowanie wstępnie żelowanej skrobi
IN191239B (de) 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
US6500463B1 (en) * 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
IL134701A0 (en) * 2000-02-23 2001-04-30 J P M E D Ltd Homogeneous solid matrix containing vegetable proteins
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20030049312A1 (en) * 2000-03-15 2003-03-13 Frauke Gaedcke Hard gelatine capsules containing sustained-release plant extracts and method for production thereof
KR20030011797A (ko) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 맛이 차폐된 과립형 입자
JP4570725B2 (ja) * 2000-04-05 2010-10-27 大塚製薬株式会社 医薬製剤用組成物
US6468568B1 (en) 2000-06-16 2002-10-22 General Mills, Inc. Oligosaccharide encapsulated mineral and vitamin ingredients
US6436453B1 (en) 2000-06-16 2002-08-20 General Mills, Inc. Production of oil encapsulated minerals and vitamins in a glassy matrix
US6558718B1 (en) 2000-06-19 2003-05-06 General Mills, Inc. Nutrient clusters for food products and methods of preparation
IT1318625B1 (it) * 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
KR100863146B1 (ko) 2000-07-17 2008-10-14 아스텔라스세이야쿠 가부시키가이샤 경구 흡수 개선 의약 조성물
RU2281757C2 (ru) * 2000-09-19 2006-08-20 Дайити Фармасьютикал Ко., Лтд. Фармацевтическая композиция
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
EP1333807A4 (de) * 2000-10-13 2005-06-29 Advancis Pharmaceuticals Erythromycin-derivate mit verzögerter freisetzung
AU2002224053A1 (en) * 2000-11-21 2002-06-03 Kyorin Pharmaceutical Co. Ltd. Dry syrup preparations
US7008646B2 (en) 2001-02-20 2006-03-07 Patrick Thomas Spicer Cubic liquid crystalline compositions and methods for their preparation
KR100460282B1 (ko) * 2001-12-10 2004-12-08 고토부키 세이야쿠 가부시키가이샤 쓴 맛을 경감한 경구투여제제 조성물
US20040013737A1 (en) * 2002-07-19 2004-01-22 Philippe Becourt Taste masked oral composition of telithromycin
US7431986B2 (en) * 2002-07-24 2008-10-07 General Mills, Inc. Encapsulation of sensitive components using pre-emulsification
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20040146553A1 (en) * 2002-12-23 2004-07-29 Aventis Pharma S.A. Compositions for oral administration of active principles requiring masking of taste
KR100508992B1 (ko) * 2003-03-31 2005-08-17 한국유나이티드제약 주식회사 쓴 맛을 개선한 클래리스로마이신 경구용 약제 조성물 및 그의 제조 방법
EP1648418A4 (de) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc Antibiotisches produkt, seine verwendung und formulierung
EP1648415A4 (de) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc Antibiotisches produkt, seine verwendung und formulierung
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1658034A4 (de) * 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc Antibiotisches produkt, seine verwendung und formulierung
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8349361B2 (en) 2003-10-15 2013-01-08 Fuji Chemical Industry Co., Ltd. Composition for rapid disintegrating tablet in oral cavity
KR101159617B1 (ko) * 2003-10-15 2012-06-27 후지카가쿠고교가부시키가이샤 구강내 속붕해성 정제
JP3841804B2 (ja) * 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
CN100438914C (zh) * 2003-10-15 2008-12-03 富士化学工业株式会社 用于口腔内快速崩解的片剂的组合物
WO2005044236A1 (en) * 2003-10-27 2005-05-19 Control Delivery Systems, Inc. Suspension delivery system for the sustained and controlled local release of pharmaceuticals
JP2007513139A (ja) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 安定性の改善した多粒子組成物
JP2007513145A (ja) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 医薬用多微粒子の製造方法
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
JP2007513143A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押出機を使用して好ましくはポロクサマーおよびグリセリドを含む多粒子アジスロマイシン組成物を製造するための噴霧凝固法
CA2549225A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
KR101078576B1 (ko) * 2004-06-03 2011-11-01 다이쇼 세이야꾸 가부시끼가이샤 경구 제제 및 그의 제조 방법
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
KR100691608B1 (ko) * 2005-02-21 2007-03-12 (주)나노하이브리드 염기성 고분자가 첨가된 유리 염기형 약물과 층상형 규산염의 하이브리드 및 그의 제조방법
JP2006232789A (ja) * 2005-02-28 2006-09-07 Sawai Pharmaceutical Co Ltd 経口製剤用組成物及びその製造方法
US7803413B2 (en) 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
PT2001445E (pt) * 2006-03-16 2014-10-24 Euro Celtique Sa Esferoides farmacêuticos
EP2010154A2 (de) * 2006-04-27 2009-01-07 Takeda Pharmaceutical Company Limited Feste pioglitazon-zubereitung mit maskiertem geschmack
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2317873A4 (de) * 2008-07-22 2015-04-22 Gen Mills Inc Obstprodukte mit omega-3-fettsäuren
TW201041507A (en) 2009-04-30 2010-12-01 Dow Agrosciences Llc Pesticide compositions exhibiting enhanced activity and methods for preparing same
TW201041509A (en) 2009-04-30 2010-12-01 Dow Agrosciences Llc Pesticide compositions exhibiting enhanced activity
TW201041510A (en) 2009-04-30 2010-12-01 Dow Agrosciences Llc Pesticide compositions exhibiting enhanced activity
AU2010254831B2 (en) * 2009-06-05 2015-11-19 General Mills, Inc. Encapsulated omega-3 fatty acids for baked goods production
MX378797B (es) 2009-09-28 2025-03-10 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US8454694B2 (en) 2011-03-03 2013-06-04 Warsaw Orthopedic, Inc. Interbody device and plate for spinal stabilization and instruments for positioning same
JP6392207B2 (ja) * 2013-03-26 2018-09-19 キッセイ薬品工業株式会社 シロドシンの苦味をマスキングした経口投与製剤
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3034897A (en) * 1960-12-09 1962-05-15 Eastman Kodak Co Method for preparing bakery products using mixed partial ester compositions
US3034898A (en) * 1960-12-09 1962-05-15 Eastman Kodak Co Mixed partial ester compositions
US3673106A (en) * 1969-06-18 1972-06-27 Kraftco Corp Emulsifier system
JPS5322141B2 (de) * 1972-12-14 1978-07-06
US4315041A (en) * 1979-11-19 1982-02-09 Riken Vitamine Oil Co., Ltd. Emulsifier composition and quality improvement method for starch containing food
US4327077A (en) * 1981-05-29 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
SE8203953D0 (sv) * 1982-06-24 1982-06-24 Astra Laekemedel Ab Pharmaceutical mixture
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物

Also Published As

Publication number Publication date
HK1004372A1 (en) 1998-11-27
DK0826376T3 (da) 2007-04-16
EP0826376B1 (de) 2007-01-24
AU5515296A (en) 1996-11-21
DE69636864D1 (de) 2007-03-15
KR100404293B1 (ko) 2004-02-18
US5972373A (en) 1999-10-26
CA2219991A1 (en) 1996-11-07
ES2279519T3 (es) 2007-08-16
CN1170596C (zh) 2004-10-13
EP0826376A4 (de) 2004-06-09
DE69636864T2 (de) 2007-05-31
WO1996034628A1 (fr) 1996-11-07
CN1183050A (zh) 1998-05-27
CA2219991C (en) 2007-10-30
AU694655B2 (en) 1998-07-23
KR19990008249A (ko) 1999-01-25
EP0826376A1 (de) 1998-03-04
JP3470198B2 (ja) 2003-11-25

Similar Documents

Publication Publication Date Title
DE69636864D1 (de) Mittel zur oralen verabreichung
MX9207630A (es) Composiciones farmceuticas de sabor enmascarado.
FI973147A0 (fi) Makua peittäviä nesteitä
EP1161956A4 (de) Medikamentenzusammensetzung
AU8296987A (en) Pharmaceutical composition comprising fluticasone propionate
WO1998035658A3 (de) Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon
NO910213D0 (no) Fremgangsmaate for fremstilling av orale legemiddelformer av pimobendan.
PT998287E (pt) Utilizacao de levobupivacaina
EA199600029A3 (ru) Оральная композиция, содержащая s (+)-этодолак, способ её получения
WO1999044608A8 (en) New use
NO923643L (no) Legemiddel for behandling av gastrointestinale forstyrrelser
DK0539479T3 (da) Heterocykliske forbindelser
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
EE9900162A (et) Rinnavähi vältimise meetod, farmatseutiline preparaat ja toode ning toimeaine kasutamine
DE59605959D1 (de) Verwendung von Immunglobulin-Präparationen zur Herstellung eines Medikaments zur oralen Verabreichung zur Behandlung und Prophylaxe chronischer Schmerzzustände
EP0848948A4 (de) Lang wirksames mittel zur rektalen verabreichung
WO2000061124A3 (en) Use off cell membrane penetrating indigoid bisindole derivatives
ATE100095T1 (de) 2,2-dimethylchromenderivate, verfahren zur herstellung und diese enthaltende pharmazeutische zusammenstellungen.
WO1996037183A3 (en) Compositions capable of masking astringent taste sensations
ATE256465T1 (de) Orale arzneimittel zubereitung von piperdinoalkanole in gelöster form
ID26132A (id) Pembuatan untuk pengobatan dari gangguan fungsi ereksi
AU6601900A (en) Silicon derivatives of fragrant, flavouring and medicinal substances
MX9605131A (es) Formulacion estable de lactona de 7-etil-camptotecina y metodo para usar la misma.
FR2738818B1 (fr) Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament
RU98112055A (ru) Способ лечения заболеваний слизистой оболочки рта у больных с вторичными иммунодефицитами

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0826376

Country of ref document: EP